Agoracom Blog Home

Posts Tagged ‘blood clot’

VIDEO – Valeo Pharma Agreement Supports $30M Annual Revenue Target From Blood Thinner Product Alone

Posted by AGORACOM-JC at 4:12 PM on Wednesday, October 13th, 2021
Valeo pharma 300x300

Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.  

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.   

Q3 Highlights:  

  • Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.
  • Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.
  • Record 9 months revenues at $10.2 million , up 94%

In today’s announcement, Valeo Pharma Obtains Listings for Redesca from Two GPO Representing 700 Hospitals and Healthcare Facilities Across Canada.

Highlighted by the following;

  • 2 Group Purchasing Organizations listing agreements cover, Redesca™ and Redesca HP™, as well as 3 other Valeo hospital products
  • The 2 multi-year product listings commenced on October 1, 2021
  • The GPOs together represent more than 700 hospitals and healthcare facilities across 5 provinces including Ontario

The agreement above supports $30M annual revenue target From blood thinner product alone!

As you can see above, Valeo is hitting on all cylinders with tremendous revenue growth from new great drugs hitting the Canadian markets as we speak. As a result, the company estimates annual revenue of $160M by 2025.

Now sit back, relax and watch this powerful interview with Steve Saviuk CEO of Valeo Pharma.

VIDEO – Valeo Pharma (VPH:CSE) Reported Record Q3-21 Revenue of $5.7 million, up 280% over Q3-20

Posted by AGORACOM-JC at 5:22 PM on Thursday, September 23rd, 2021
Valeo pharma 300x300

Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies. 

The company recently released Q3 results and highlights:

·  Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.

·  Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.

·  Record 9 months revenues at $10.2 million , up 94%.

·  Private and public reimbursement coverage expanding for Redesca®

·  New corporate structure completed with full commercial activities ongoing for Redesca®, Enerzair® Breezhaler® and Atectura® Breezhaler®

As you can see above, Valeo is hitting on all cylinders with tremendous revenue growth from new great drugs hitting the Canadian markets as we speak. As a result, the company estimates annual revenue of $160M by 2025.

Now sit back, relax and watch this powerful interview with Steve Saviuk CEO of Valeo Pharma.

VIDEO – Valeo Pharma (VPH:CSE) Reported Record Q2 Revenue of $2.65M, CEO Expects Q3 To Increase More Than 50%

Posted by AGORACOM-JC at 12:23 PM on Monday, July 5th, 2021
http://blog.agoracom.com/wp-content/uploads/2021/03/VPH-square.jpg

Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies. 

The smile on CEO Steve Saviuk says it all. The company recently released Q2 results and highlights:

  • Q2-21 record revenues of $2.65 million, up 27% vs Q2-20 and up 42% over prior quarter
  • Q3-21 revenues expected to increase by more than 50% over Q2-21
  • Redesca (blood thinner) launched in late Q2-21
  • Commercial shipments of the company’s asthma drugs commenced following national respiratory sales force deployment
  • Closed upsized $6.645 million debenture placement
  • Closed $11.5 million bought deal

As you can see above, Valeo is hitting on all cylinders with tremendous revenue growth from new great drugs hitting the Canadian markets as we speak. As a result, the company estimates annual revenue of $160M by 2025.

Now sit back, relax and watch this powerful interview with Steve Saviuk CEO of Valeo Pharma.

AGORACOM Small Cap 60: Valeo $VPH $VPHIF Blood Clot Prevention Drug Approved By Ont Drug Plan, Other Provinces To Follow Suit $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 10:43 AM on Friday, May 7th, 2021
http://blog.agoracom.com/wp-content/uploads/2021/03/VPH-square.jpg